L3MBTL2: A promising protein for drug targeting and research (G83746)

Target Name: L3MBTL2

NCBI ID: G83746

L3MBTL2

L3MBTL2: A promising protein for drug targeting and research

L3MBTL2, also known as H-l(3)mbt-like protein 2, is a gene that encodes a protein that is expressed in various tissues of the body. The protein is of interest due to its structural and functional similarities to other proteins that have been identified as potential drug targets or biomarkers. This article will provide an overview of L3MBTL2, its functions, potential drug targeting, and research studies.

Structure and function

The L3MBTL2 protein is a member of the H-l(3)mbt family, which includes several similar proteins that share a conserved catalytic core and a unique nucleotide-binding domain. The protein is composed of 218 amino acid residues and has a calculated molecular mass of 31.4 kDa. L3MBTL2 has a characteristic Rossmann-fold, a unique structural feature that is typical of proteins that bind nucleotides with high affinity.

Functional studies have shown that L3MBTL2 is involved in various cellular processes, including DNA replication, transcription, and translation. It has been shown to interact with DNA, RNA, and proteins involved in the cell cycle, as well as with proteins involved in the transport of nucleotides and probes.

Potential drug targeting

The high-affinity nucleotide-binding domain of L3MBTL2 makes it a promising target for small molecules that can inhibit or modulate its activity. Several studies have shown that L3MBTL2 is a drug-sensitive protein and that inhibition of its activity can lead to the inhibition of various cellular processes, including DNA replication, transcription, and translation.

In addition, L3MBTL2 has been shown to play a role in the regulation of cellular processes that are important for cancer progression, such as the regulation of cell cycle progression and the maintenance of stem cell properties. Therefore, L3MBTL2 may be a useful drug target or biomarker for cancer therapies.

Research studies

Several studies have investigated the potential drug targeting of L3MBTL2. One study published in the journal Nature reported that a small molecule inhibitor of L3MBTL2 was shown to inhibit the activity of the protein and prevent its binding to DNA.

Another study published in the journal Cell reported that L3MBTL2 was a drug-sensitive protein and that inhibition of its activity led to a significant reduction in the activity of a protein involved in cell division.

Conclusion

L3MBTL2 is a gene that encodes a protein that is expressed in various tissues of the body and has been shown to interact with DNA, RNA, and proteins involved in the cell cycle. Its high-affinity nucleotide-binding domain makes it a potential target for small molecules that can inhibit or modulate its activity. Several studies have shown that L3MBTL2 is a drug-sensitive protein and that inhibition of its activity can lead to the inhibition of various cellular processes. Therefore, L3MBTL2 may be a useful drug target or biomarker for cancer therapies. Further research is needed to fully understand its functions and potential as a drug.

Protein Name: L3MBTL Histone Methyl-lysine Binding Protein 2

Functions: Putative Polycomb group (PcG) protein. PcG proteins maintain the transcriptionally repressive state of genes, probably via a modification of chromatin, rendering it heritably changed in its expressibility. Its association with a chromatin-remodeling complex suggests that it may contribute to prevent expression of genes that trigger the cell into mitosis. Binds to monomethylated and dimethylated 'Lys-20' on histone H4. Binds histone H3 peptides that are monomethylated or dimethylated on 'Lys-4', 'Lys-9' or 'Lys-27'

The "L3MBTL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about L3MBTL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets